Silvia S. Jurisson
Inorganic and Radiopharmaceutical Chemistry, Technetium Clathrochelates
- BS, University of Delaware, 1978
- PhD, University of Cincinnati, 1982
- Vice-Chair (2008), Chair-Elect (2009), Chair (2010) for the Division of Nuclear Chemistry and Technology, American Chemical Society
- Member (2006-2012), Board of Directors, Society of Radiopharmaceutical Science (elected)
- Professor, Missouri, 2001-present
- Associate Professor, Missouri, 1997-2001
- Assistant Professor, Missouri, 1991-1997
- Research Investigator, MURR, 1995-present
- Senior Research Investigator, Squibb and Bristol-Myers Squibb, 1989-1991
- Research Investigator, The Squibb Institute for Medical Research, 1986-1989
- Postdoctorate, University of Missouri-Columbia, 1984-1986
- Postdoctorate, Australian National University, 1984
- Postdoctorate, University of New South Wales, 1983-1984
Honors and Awards
- 2000 MU Faculty Development Leave Award
- 1996 MU Summer Research Fellowship
- 1996 MU Alumni Faculty Incentive Award
- 1995 MU Arts & Science Assistant Professor Travel Award
- 1993 MU Faculty Development Award
- 1992 MU Summer Research Fellowship
- 1981-1982 Procter & Gamble Research Fellowship, University of Cincinnati
- 1980 University of Cincinnati Research Council Summer Fellowship
- 1979-1981 Research Associates Fellowship, University of Cincinnati
- 1979-1980 Senior Teaching Assistant for General Chemistry and Laboratory, University of Cincinnati
- 1979 Henry Hochstetter Award for Excellence in Teaching
My research interests involve two very different, yet related, areas of radioinorganic chemistry. One area focuses on the utilization of gamma and beta emitting radiometals in the development of potential diagnostic and therapeutic radiopharmaceuticals. The second area addresses methods for the detection and separation of radiometals, in particular technetium-99, for minimization and safe storage of radioactive waste. Both research areas are multidisciplinary and therefore involve collaborations with other scientists within the department as well as in other departments.
The area of radiopharmaceutical chemistry involves radioisotope production methods, syntheses of ligands and coordination complexes, radiochemical syntheses, development of separation methods, biochemistry, biology and radiology. We are focusing on the development of high specific activity radionuclides for these applications, in particular, Tc-99m, Re-188, Rh-105, Au-199, Pm-149, Ho-166, Lu-177, Ga-68, In-111, and As-72. We are using combinatorial chemistry approaches as well as traditional chemistry approaches to design better targeting molecules for receptors on tumors. We have been interested in the development of the chemistry, radiochemistry and biochemistry of potential diagnostic and therapeutic radiopharmaceuticals whose mode of targeting uses small biological molecules (e.g., peptides, antibody fragments, etc.). The primary targets to date have been melanoma, breast cancer, prostate cancer and neuroendocrine cancers. We have developed new ligand systems for rhodium(III), gold(III), and various oxidations states of rhenium and technetium. The ligand systems developed include thioether, phosphine, amine, imine, Schiff base, and thiolate functionalities for coordination to the various metals. Our emphasis is on developing metal complexes that are kinetically inert under physiological conditions. Our studies include the synthesis of new ligand systems (generally tetradentate), the synthesis of the transition metal complexes, the synthesis of the radiotracer analogs of these complexes, the determination of the stability of these complexes under physiological conditions, the determination of the binding of the various complexes to the appropriate receptors (in vitro), and the determination of the in vivo behavior of these complexes in both normal and tumor model mice. We are also interested in the similarities and differences in the chemistry of analogous Tc and Re compounds, such as the rates of formation and substitution, the mechanisms of formation, and their electrochemical behavior. These studies are important to the development of potential therapeutic radiopharmaceuticals based on Re.
The area of radioenvironmental chemistry involves radiochemistry, inorganic chemistry and analytical chemistry. Technetium-99 is a long-lived radionuclide produced in about 6% yield from the fission of U-235 and Pu-239 used as fuel in nuclear reactors and weapons. Thus, it is a large component of the waste generated from the nuclear weapons era and from nuclear fuel reprocessing. The combination of its long half-life (212,000 years) and its mobility in the environment as the oxoanion pertechnetate makes Tc-99 a problem for long term storage and environmental migration. We have investigated the use of supramolecular hosts and phosphinimines to selectively bind pertechnetate, and sulfide reduction in the presence of mineral phases to investigate the immobilization of Tc-99.
Summary (updated on Oct 2010)
>100 papers in refereed journals
- “Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model”, S. R. Lane, P. Nanda, T. L. Rold, G. L. Sieckman, S. D. Figueroa, T. J. Hoffman, S. S. Jurisson, C. J. Smith, Nucl. Med. Biol. 2010, 37, 751-761.
- “In Vitro Structure-Activity Relationship of Re-Cyclized Octreotide Analogues”, S. F. Dannoon, H. M. Bigott-Hennkens, F. Gallazzi, L. Ma, M. R. Lewis, S. S. Jurisson, Nucl. Med. Biol. 2010, 37, 527-537.
- “Gold(III) Bis-Thiosemicarbazonato Complexes: Synthesis, Characterization, Radiochemistry and X-ray Crystal Structure Analysis”, B. N. Bottenus, P. Kan, T. Jenkins, B. Ballard, T. L. Rold, C. Barnes, C. Cutler, T. J. Hoffman, M. A. Green, S. S. Jurisson, Nucl. Med. Biol. 2010, 37, 41-49.
- “Potential Interferences on the Pertechnetate-Sulfide Immobilization Reaction”, Y. Liu, J. Terry, S. S. Jurisson, Radiochimica Acta 2009, 97, 33-41.
- “99mTc(CO)3-DTMA (DTMA = Diethylenetriamine Monoacetate) Bombesin Conjugates Having High Affinity of the GRP Receptor”, S. R. Lane, B. Veerendra, T. L. Rold, G. L. Sieckman, T. J. Hoffman, S. S. Jurisson, C. J. Smith, Nucl. Med. Biol. 2008, 35, 263-272.
- “Fluorescent Phosphinimine as a Possible Precursor to an Anionic and Fluorescent Sensor for Tc-99”, L. M. Arrigo, M. Galenas, D. B. Bassil, S. A. Tucker, R. Kannan, K. V. Katti, C. L. Barnes, S. S. Jurisson, Radiochimica Acta 2008, 96, 835-844.
- “Pertechnetate Immobilization with Amorphous Iron Sulfide”, Y. Liu, J. Terry, S. S. Jurisson, Radiochimica Acta 2008, 96, 823-833.
- “Synthesis and In Vitro Evaluation of a Re-cyclized Somatostatin Derivative Series”, H. M. Bigott-Hennkens, S. Junnotula, L. Ma, F. Gallazzi, M. R. Lewis, S. S. Jurisson, J. Med. Chem. 2008, 51, 1223-1230.
- “Phosphinimines as Selective Extractants for Tc-99 Pertechnetate”, L. M. Arrigo, M. Galenas, R. Kannan, K. V. Katti, S. S. Jurisson, Radiochimica Acta, 2008, 96, 175-181.
- “Pertechnetate Immobilization in Aqueous Media with Hydrogen Sulfide under Anaerobic and Aerobic Environments”, Y. Liu, J. Terry, S. Jurisson, Radiochim. Acta 2007, 95, 1-9.
- “In Vivo Evaluation and MicroPET/CT Imaging of a Prostate Cancer Mouse Model using Copper-64 Bombesin Analogs: Side by Side Comparison of the CB-TE2A and DOTA Chelation Systems”, J. C. Garrison, T. L. Rold, G. L. Sieckman, S. D. Figueroa, W. A. Volkert, S. S. Jurisson, T. J. Hoffman, J. Nucl. Med. 2007, 48, 1327-1337.
- “Preparation and Biological Evaluation of 111In, 177Lu and 90Y Labeled DOTA Analogues Conjugated to B72.3”, H. Mohsin, J. Fitzsimmons, T. Shelton, T.J. Hoffman, C.S. Cutler, M.R. Lewis, P.S. Athey, G. Gulyas, G.E. Kiefer, R.K. Frank, J. Simon, S.Z. Lever, S.S. Jurisson, Nucl. Med. Biol. 2007, 34, 493-502.
- "Radiolanthanide-Labeled Monoclonal Antibody CC49 for Radioimmunotherapy of Cancer: Biological Comparison of DOTA Conjugates and 149Pm, 166Ho and 177Lu", H. Mohsin, G. Sivaguru, F. Jia, M.J. Hudson, T.D. Shelton, T.J. Hoffman, C.S. Cutler, A.R. Ketring, P.S. Athey, J. Simon, R.K. Frank, S.S. Jurisson, M.R. Lewis, Bioconjugate Chem. 2006, 17(2), 485-492.
- "Preparation of Cyclotron-Produced Re-186 and Comparison with Reactor-Produced Re-186 and Generator-Produced Re-188 for the Labeling of Bombesin", M.E. Moustapha, G.J. Ehrhardt, C.J. Smith, L.P. Szajek, W.C. Eckelman, S.S. Jurisson, Nucl. Med. Biol. 2006, 33(1), 81-89.
- "Reactivity of Re(V) Oxo Schiff Base Complexes with Phosphine Ligands: Rearrangement and Reduction Reactions", P.D. Benny, J.L. Green, H.P. Engelbrecht, C.L. Barnes, S.S. Jurisson, Inorg. Chem. 2005, 44, 2381-2390.
- "Radioiodination of Rhenium Cyclized Alpha-Melanocyte Stimulating Hormone
Resulting in Enhanced Radioactivity Localization and Retention in Melanoma", Z. Cheng, J. Chen, T.P. Quinn, and S.S. Jurisson, Cancer Res. 2004, 64(4), 1411-1418.
- "Synthesis and Characterization of Novel Rhenium(V) Tetradentate N2O2 Schiff Base Monomer and Dimer Complexes", P.D. Benny, C.L. Barnes, P.M. Piekarski, J.D. Lydon, S.S. Jurisson, Inorg. Chem. 2003, 42, 6519-6527.
- "Aminecarboxylate and Octreotide Complexes with No Carrier Added 177Lu, 166Ho and 149Pm", W. Li, C.J. Smith, T. Hoffman, C.S. Cutler, A.R. Ketring, S.S. Jurisson, Nucl. Med. Biol. 2003, 30, 241-251.
- "Extraction of Pertechnetate and Perrhenate from Water with Deep Cavity [CpFe(arene)]+ Derivatized Cyclotriveratrylenes", J.A. Gawenis, K.T. Holman, J.L. Atwood, S.S. Jurisson, Inorg. Chem. 2002, 41, 6028-6031.
- "Modification of the Structure of a Metallopeptide: Synthesis and Biological Evaluation of 111In Labeled DOTA Conjugated Rhenium Cyclized a-MSH Analogs", Z. Chen, J. Chen, N.K. Owen, T.P. Quinn, S.S. Jurisson, J. Med. Chem. 2002, 45, 3048-3056.
- "Ion-Pairing as a Strategy for Extraction by Modified Supercritical Carbon Dioxide: Extraction of Radioactive Metal Ions", J.A. Gawenis, J.F. Kauffman, S.S. Jurisson, Anal. Chem. 2001, 73, 2022-2026.
- "Synthesis, Characterization and Radiochemistry of Gold(III) Tetradentate Schiff Base Complexes. X-ray Crystal Structure of [Au(propylenebis(salicylideneamine))]Cl-2.5 H2O and [Au(ethylenebis(salicylideneamine))]PF6", S. Jurisson, S.L. Barnholtz, J.D. Lydon, G. Huang, M. Venkatesh, C.L. Barnes, A. R. Ketring, Inorg. Chem. 2001, 40, 972-976.
- "Development of an In Vitro Model for Assessing the In Vivo Stability of Lanthanide Chelates" W.P. Li, D.S. Ma, C. Higginbotham, T. Hoffman, A.R. Ketring, S.S. Jurisson, Nucl. Med. Biol. 2001, 28, 145-154.
- J. Chen, Z. Cheng, T. J. Hoffman, S. S. Jurisson, T. P. Quinn,
Melanoma Targeting Properties of 99mTc-Labeled Cyclic Alpha-Melanocyte Stimulating Hormone Peptide Analogs, Cancer Res. 2000, 60, 5649-5658.
- N. Goswami, W. Nef, R. Alberto, C. Higginbotham, W. A. Volkert, S. S. Jurisson
Rhodium-105 Tetrathioether Complexes: Radiochemistry and Initial Biological Evaluation, Nucl. Med. Biol. 1999, 26, 951-957.
- "Potential Technetium Small Molecule Radiopharmaceuticals", S.S. Jurisson, J.D. Lydon Chem. Rev. 1999, 99, 2205-2218 (invited paper).
- Oxygen Exchange on ReO4- and TcO4- by 17O-NMR
S. S. Jurisson, R. K. Murmann
Inorg. Chem. 1999, 38, 3919-2921.
- M. F. Giblin, N. Wang, T. J. Hoffman, S. Jurisson, T. P. Quinn,
Design and Characterization of Alpha-Melanotropin Peptide Analogs Cyclized Through Rhenium Metal Coordination
Proc. Nat. Acad. Sci. 1998, 95, 12814-12818.
- N. Goswami, R. Alberto, C. L. Barnes, S. S. Jurisson
Rhodium(III) Complexes with Acyclic Tetrathioether Ligands. Effects of Backbone Chain Length on the Conformation of the Rh(III) Complex
Inorg. Chem. 1996, 35, 7546-7555.
- K. T. Holman, M. M. Halihan, S. S. Jurisson, J. L. Atwood, R. S. Burkhalter, A. R. Mitchell, J. W. Steed
Inclusion of Neutral and Anionic Guests Within the Cavity of p-Metalated Cyclotriveratrylene
J. Am. Chem. Soc. 1996, 118, 9567-9576.
- K. T. Holman, M. M. Halihan, J. W. Steed, S. S. Jurisson, J. L. Atwood
A Novel Organometallic Host for the Perrhenate Anion
J. Am. Chem. Soc. 1995, 117, 7848-9.
supported by NIBIB T32 EB004822